Clinical study of Shugan Hewei granule in the treatment of refractory gastroesophageal reflux disease with qi stagnation and phlegm obstructio
- Conditions
- gastroesophageal reflux disease
- Registration Number
- ITMCTR2000003657
- Lead Sponsor
- Yueyang Hospital of Integrated Traditioanl Chinese and Western Medicine,Shanghai University of Traditional Chinese Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- Not specified
A. It was in accordance with the diagnostic criteria of qi stagnation and phlegm resistance type of acid vomiting (gastroesophageal reflux disease).
B. Before this study, patients with gastroesophageal reflux disease (GERD) were treated with standard dose PPI for four weeks or more.
C. The age is 18-70 years old, with no gender limit.
A. Patients with one of the following diseases: peptic ulcer, history of gastroesophageal and duodenal surgery, Zhuo AI syndrome, primary esophageal motility disorders (such as achalasia, scleroderma, primary esophageal spasm), malignant lesions of upper gastrointestinal tract, coronary heart disease, diabetes, drug-induced esophagitis, and psychotic patients.
B. Pregnant women and allergic constitution patients.
C. The patient himself is the researcher directly involved in this clinical study.
Study & Design
- Study Type
- Interventional study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.